Clinical Trials Logo

Delirium clinical trials

View clinical trials related to Delirium.

Filter by:

NCT ID: NCT03133208 Active, not recruiting - Sepsis Clinical Trials

Sepsis Associated Encephalopathy (SAE) Biomarkers

Start date: June 1, 2017
Phase:
Study type: Observational

Sepsis associated encephalopathy (SAE) is a poorly understood acute cerebral dysfunction that frequently appears in the setting of sepsis induced systemic inflammation. In fact, altered mentation is recognized as an independent predictor of death and poor outcomes in patients with sepsis. SAE may be manifested by a number of symptoms characterized by a change in baseline behavior, attention, alertness, cognition, or executive functioning. It occurs in the absence of direct Central Nervous System (CNS) infection, and the exact pathophysiology is of SAE is unknown, but theoretically seems to encompass a constellation of mechanisms such as impairment of the blood brain barrier (BBB), endothelial dysfunction, alteration in cerebral blood flow and neurotransmission, circulating inflammatory mediators, cellular hypoxia, and metabolic disturbances, that ultimately result in neuronal dysfunction and cell death. SAE is characterized by an altered mental status (AMS) that ranges from delirium to coma, and can lead to long-term cognitive impairment. SAE may appear early in the course of sepsis, and is often underestimated as an independent factor of mortality, yet the pathophysiology of SAE remains unknown, and there is a lack of specific investigations available to clinicians. Studies have evaluated biomarkers as prognostic tools. The Investigator propose to measure neuron specific enolase (NSE), S-100B, glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), Tau protein, Copeptin, spectrin breakdown products (SBDP 145, SBDP150), αII-spectrin N-terminal fragment (SNTF), neurofilament light and heavy chains (NF-L, NF-H), myelin basic protein (MBP), secretoneurin (SN), and other peptide levels in the serum of sepsis patients who develop altered mental status, to evaluate the kinetics of said biomarkers for 72 hours. The Investigator will monitor the course of the patients' hospitalization to determine whether there are biomarker correlates with survival and outcomes, including neurologic impairment. Finally, this investigation may provide a mechanistic pathway that defines the development of AMS in septic patients.

NCT ID: NCT03132701 Completed - Emergence Delirium Clinical Trials

The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children

Start date: June 8, 2017
Phase: N/A
Study type: Interventional

Evaluation of prevention of emergence delirium and analgesic effect of magnesium on children

NCT ID: NCT03132168 Completed - Clinical trials for Post-operative Delirium

Postoperative Delirium in Patients Undergoing Radical Cystectomy

Start date: January 10, 2018
Phase: N/A
Study type: Interventional

In this study, post-operative delirium will be measured in patients undergoing surgery for bladder resection, and associated microRNA biomarkers will be evaluated in patients considered delirious and non-delirious after surgery.

NCT ID: NCT03131375 Completed - Blood Pressure Clinical Trials

Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia

Start date: May 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Dexmedetomidine (DEX) is safe and effective in reducing ED following sevoflurane anesthesia. The investigators intend to study the efficacy of DEX in reducing ED in children undergoing tonsillectomy with and without adenoidectomy using total intravenous anesthesia (TIVA) with propofol .

NCT ID: NCT03130231 Completed - Clinical trials for Postoperative Delirium

Predictive Value of β2-microspheres for Postoperative Delirium

Start date: October 1, 2015
Phase:
Study type: Observational

This study evaluated the predictive value of β2-microspheres for postoperative delirium (POD) in the elderly after orthopedic surgery. For this purpose, the levels of β2-microspheres in plasma and cerebrospinal fluid were compared between the POD and non-POD groups.

NCT ID: NCT03128671 Completed - Clinical trials for Cognitive Impairment

Family Automated Voice Reorientation Study

FAVoR
Start date: May 19, 2017
Phase: N/A
Study type: Interventional

This randomized clinical trial tests a cognitive reorientation intervention to prevent delirium in the intensive care unit using scripted audio messages, recorded by the patient's family and played at hourly intervals during daytime hours, to provide information about the ICU environment to the patient (the Family Automated Voice Reorientation intervention, FAVoR). The investigators hypothesize that providing ongoing orientation to the ICU environment through recorded audio messages in a voice familiar to the patient will enable the patient to more accurately interpret the environment and reduce risk of delirium. Increasing awareness of daytime by cuing patients during waking hours may also improve day/night orientation, nighttime sleep/rest, and further reduce risk of delirium.

NCT ID: NCT03125252 Completed - Delirium Clinical Trials

Impact of Non-pharmacological Prevention Measures on the Incidence of Delirium in Adult Intensive Care Units

DELIREA
Start date: October 27, 2016
Phase: N/A
Study type: Interventional

The main objective is to evaluate the impact of the "bundle of actions" on the delirium's incidence in resuscitation patients during their stay in the service, compared to a conventional treatment. The investigators therefore hypothesize that a set of coordinated paramedical actions in the prevention of delirium would reduce its incidence by 15% compared to conventional care.

NCT ID: NCT03124303 Recruiting - Delirium Clinical Trials

Interventions for Postoperative Delirium: Biomarker-3

IPOD-B3
Start date: February 13, 2017
Phase:
Study type: Observational

The IPOD-B3 study aims to characterize the relationship between premorbid brain activity and postoperative delirium in patients undergoing major surgery. This is a expansion of the NeuroVISION Bolt-On study, NCT01980511.

NCT ID: NCT03120442 Enrolling by invitation - Clinical trials for Postoperative Delirium

Postoperative Delirium After Total Knee Arthroplasty Under Regional Anesthesia

Start date: June 14, 2017
Phase: N/A
Study type: Interventional

Postoperative delirium after total knee replacement surgery has been related to significant morbidity and mortality among high risk patients. Anesthetic care might play a role in the development of postoperative delirium. The purpose of this study is to compare the incidence of postoperative delirium between different intraoperative sedation regimen. Delirium assessment using standardized screening tools will be done every 8 hours after surgery.

NCT ID: NCT03117712 Completed - Clinical trials for Postoperative Delirium

Cerebral Blood Supply During Cardiopulmonary Bypass

Start date: May 1, 2017
Phase:
Study type: Observational

Postoperative delirium is an acute and fluctuating state of confusion and disorientation with an incidence of 25-70% after cardiac surgery. Possible reasons for this multifactorial complication are hypoperfusion, cerebral microembolization and inflammatory response, which eventually lead to regional or global imbalance between cerebral oxygen demand and supply. Adequate cerebral blood supply depends sufficient blood supply via the vertebral arteries and the internal carotid arteries. The aim of this preliminary study is to investigate if patients who develop delirium after open-heart surgery show differences in their cerebral blood flow during cardiopulmonary bypass (CPB) in extracerebral arterial vessels compared to those patients without delirium.